Efficacy of weekly teriparatide does not vary by baseline fracture probability calculated using FRAX

Osteoporosis International

Volumn 26, Issue 9, 2015, Pages 2347-2353

  Harvey, N C ^a   Kanis, J A ^b   Oden A ^b   Nakamura, T ^c   Shiraki, M ^d   Sugimoto, T ^e   Kuroda, T ^f   Johansson, H ^b   McCloskey, E V ^b  

^a UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^b UNIVERSITY OF SHEFFIELD   (United Kingdom)

^c NATIONAL CENTER FOR GLOBAL HEALTH AND MEDICINE   (Japan)

^d RESEARCH INSTITUTE AND PRACTICE FOR INVOLUTIONAL DISEASES   (Japan)

^e Internal Medicine 1   (Japan)

^f ASAHI KASEI PHARMA CORPORATION   (Japan)

Author keywords

Epidemiology; FRAX; Osteoporosis; Randomised controlled trial; Teriparatide; Vertebral fracture

Indexed keywords

PARATHYROID HORMONE[1-34]; PLACEBO; BONE DENSITY CONSERVATION AGENT;

AGED; ALGORITHM; ARTICLE; BONE DENSITY; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; FRAGILITY FRACTURE; HIP FRACTURE; HUMAN; MAJOR CLINICAL STUDY; MALE; MORPHOMETRICS; PHASE 3 CLINICAL TRIAL; POSTMENOPAUSE OSTEOPOROSIS; PRIORITY JOURNAL; PROBABILITY; RANDOMIZED CONTROLLED TRIAL; RISK REDUCTION; SPINE FRACTURE; TREATMENT OUTCOME; CLINICAL TRIAL; COMPLICATION; DOUBLE BLIND PROCEDURE; DRUG ADMINISTRATION; DRUG EFFECTS; HIP FRACTURES; OSTEOPOROSIS; OSTEOPOROTIC FRACTURES; PATHOPHYSIOLOGY; PROCEDURES; RISK ASSESSMENT; SPINAL FRACTURES; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ALGORITHMS; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; HIP FRACTURES; HUMANS; MALE; OSTEOPOROSIS; OSTEOPOROTIC FRACTURES; RISK ASSESSMENT; SPINAL FRACTURES; TERIPARATIDE; TREATMENT OUTCOME;

EID: 84938979336     PISSN: 0937941X     EISSN: 14332965     Source Type: Journal    
DOI: 10.1007/s00198-015-3129-7     Document Type: Article

References (25)

1. Reeve J, Meunier PJ, Parsons JA et al (1980) Anabolic effect of human parathyroid hormone fragment on trabecular bone in involutional osteoporosis: a multicentre trial. Br Med J 280:1340–1344
2. Devogelaer JP, Boutsen Y, Manicourt DH (2010) Biologicals in osteoporosis: teriparatide and parathyroid hormone in women and men. Curr Osteoporos Rep 8:154–161
3. Resmini G, Iolascon G (2011) New insights into the role of teriparatide. Aging Clin Exp Res 23(2 Suppl):30–32
4. Kanis JA McCloskey EV, Johansson H, Cooper C, Rizzoli R, Reginster J-Y, on behalf of the Scientific Advisory Board of the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO) and the Committee of Scientific Advisors of the International Osteoporosis Foundation (IOF) (2013) European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int 24:23–57
5. Vescini F, Grimaldi F (2012) PTH 1-84: bone rebuilding as a target for the therapy of severe osteoporosis. Clin Cases Miner Bone Metab 9:31–36
6. Fujita T, Fukunaga M, Itabashi A, Tsutani K, Nakamura T (2014) Once-weekly injection of low-dose teriparatide (28.2 μg) reduced the risk of vertebral fracture in patients with primary osteoporosis. Calcif Tissue Int 94(2):170–175
7. Neer RM, Arnaud CD, Zanchetta JR et al (2001) Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 344:1434–1441
8. Shrader SP, Ragucci KR (2005) Parathyroid hormone (1-84) and treatment of osteoporosis. Ann Pharmacother 39:1511–1516
9. Nakamura T, Sugimoto T, Nakano T, Kishimoto H, Ito M, Fukunaga M, Hagino H, Sone T, Yoshikawa H, Nishizawa Y, Fujita T, Shiraki M (2012) Randomized Teriparatide [human parathyroid hormone (TERIPARATIDE) 1-34] Once-Weekly Efficacy Research (TOWER) trial for examining the reduction in new vertebral fractures in subjects with primary osteoporosis and high fracture risk. J Clin Endocrinol Metab 97:3097–3106
10. Prince R, Sipos A, Hossain A, Syversen U, Ish-Shalom S, Marcinowska E, Halse J, Lindsay R, Dalsky GP, Mitlak BH (2005) Sustained nonvertebral fragility fracture risk reduction after discontinuation of teriparatide treatment. J Bone Miner Res 20:1507–1513
11. McCloskey EV, Johansson H, Oden A, Vasireddy S, Kayan K, Pande K, Jalava T, Kanis JA (2009) Ten-year fracture probability identifies women who will benefit from clodronate therapy–additional results from a double-blind, placebo-controlled randomised study. Osteoporos Int 20:811–817
12. Kanis JA, Johansson H, Oden A et al (2009) Bazedoxifene reduces vertebral and clinical fractures in postmenopausal women at high risk assessed with FRAX. Bone 44:1049–1054
13. Kim K, Svedbom A, Luo X, Sutradhar S, Kanis JA (2014) Comparative cost-effectiveness of bazedoxifene and raloxifene in the treatment of postmenopausal osteoporosis in Europe using the FRAX algorithm. Osteoporos Int 25:325–337
14. Kanis JA, Johansson H, Odén A et al (2010) A meta-analysis of the efficacy of raloxifene on all clinical and vertebral fractures and its dependency on FRAX. Bone 47:729–735
15. Kanis JA, Jönsson B, Odén A, McCloskey EV (2011) A meta-analysis of the effect of strontium ranelate on the risk of vertebral and non-vertebral fracture in postmenopausal osteoporosis and the interaction with FRAX®. Osteoporos Int 22:2347–2355, with erratum Osteoporos Int. 22: 2357-2358
16. McCloskey EV, Johansson H, Oden A, Austin M, Siris E, Wang A, Lewiecki EM, Lorenc R, Libanati C, Kanis JA (2012) Denosumab reduces the risk of osteoporotic fractures in postmenopausal women, particularly in those with moderate to high fracture risk as assessed with FRAX. J Bone Miner Res 27:1480–1486
17. Committee for Medicinal Products for Human Use (CHMP) (2006) Guideline on the evaluation of medicinal products in the treatment of primary osteoporosis. Ref CPMP/EWP/552/95Rev.2. London, CHMP. Nov 2006
18. Genant HK, Jergas M, Palermo L, Nevitt M, Valentin RS, Black D, Cummings SR (1996) Comparison f semiquantitative visual and quantitative morphometric assessment of prevalent and incident vertebral fractures in osteoporosis. J Bone Miner Res 11:984–996
19. Looker AC, Wahner HW, Dunn WL, Calvo MS, Harris TB, Heyse SP, Johnston CC Jr, Lindsay R (1998) Updated data on proximal femur bone mineral levels of US adults. Osteoporos Int 8:468–489
20. Kanis JA on behalf of the World Health Organization Scientific Group (2008a) Assessment of osteoporosis at the primary health-care level. Technical Report. WHO Collaborating Centre, University of Sheffield, UK. Accessible at http://www.shef.ac.uk/FRAX
21. Kanis JA, Johnell O, Odén A, Johansson H, McCloskey E (2008) FRAX™ and the assessment of fracture probability in men and women from the UK. Osteoporos Int 19:385–397
22. Lu Y, Fuerst T, Hui S, Genant HK (2001) Standardization of bone mineral density at femoral neck, trochanter and Ward's triangle. Osteoporos Int 12:438–444
23. Breslow NE, Day NE (1987) Statistical Methods in Cancer Research. IARC Scientific Publications No 32 Volume II:p 131-135
24. Nakano T, Shiraki M, Sugimoto T, Kishimoto H, Ito M, Fukunaga M, Hagino H, Sone T, Kuroda T, Nakamura T (2013) Once-weekly teriparatide reduces the risk of vertebral fracture in patients with various fracture risks: subgroup analysis of the Teriparatide Once-Weekly Efficacy Research (TOWER) trial. J Bone Miner MetabNov 9. [Epub ahead of print] PubMed
25. McCloskey EV, Spector TD, Eyres KS, Fern ED, O'Rourke N, Vasikaran S, Kanis JA (1993) The assessment of vertebral deformity: a method for use in population studies and clinical trials. Osteoporos Int 3(3):138–147